lung transplantation
lung healing
interstitial lung diseases
novel diseases
macrophages
NNLDs
Hanover experimental lung research project Non-neoplastic lung diseases
pulmonary research
relentless loss of lung function
efficient research
novel pharmaceuticals
novel approaches
inflammome
year survival
fresh explanted human lungs
risk of death
causes of death
irreversible remodeling
great potential
potential therapeutics
availability of human specimens
understanding MO biology
pulmonary immune system
patented new imaging techniques
Europeâ€™s largest LuTx program
targeted therapy of signalling cascades
d workflow
international multiplier
short ischemia
nintedanib
injury
translational medicine
treatment costs
lack of adequate animal models
growing EU wide challenge
main effector cell
particulate matters
COPD
group focusses
tissue viability
available grafts
difference
world
Wholesale therapeutic suppression
major obstacles
ultima ratio
key regulators
unique platform
dysfunctional reaction
goal
disease progression
early events
significant promise
MOs
end
years